Equities analysts expect Lipocine Inc (NASDAQ:LPCN) to report ($0.26) earnings per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Lipocine’s earnings. The highest EPS estimate is ($0.21) and the lowest is ($0.30). Lipocine posted earnings of ($0.16) per share during the same quarter last year, which suggests a negative year over year growth rate of 62.5%. The company is scheduled to report its next earnings report on Monday, March 5th.
On average, analysts expect that Lipocine will report full year earnings of ($1.04) per share for the current year, with EPS estimates ranging from ($1.11) to ($1.00). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.85) per share, with EPS estimates ranging from ($0.97) to ($0.63). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that cover Lipocine.
Lipocine (NASDAQ:LPCN) last issued its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.05.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. P.A.W. Capital Corp purchased a new position in shares of Lipocine in the third quarter valued at $397,000. Goldman Sachs Group Inc. purchased a new position in shares of Lipocine in the second quarter valued at $300,000. Vanguard Group Inc. grew its position in shares of Lipocine by 39.7% in the second quarter. Vanguard Group Inc. now owns 546,027 shares of the specialty pharmaceutical company’s stock valued at $2,195,000 after purchasing an additional 155,110 shares in the last quarter. Ameriprise Financial Inc. grew its position in shares of Lipocine by 18.2% in the second quarter. Ameriprise Financial Inc. now owns 155,600 shares of the specialty pharmaceutical company’s stock valued at $626,000 after purchasing an additional 24,000 shares in the last quarter. Finally, Federated Investors Inc. PA grew its position in Lipocine by 9.2% during the second quarter. Federated Investors Inc. PA now owns 88,083 shares of the specialty pharmaceutical company’s stock worth $354,000 after buying an additional 7,429 shares in the last quarter. Institutional investors own 22.06% of the company’s stock.
Shares of Lipocine (NASDAQ LPCN) traded down $0.07 during trading on Friday, reaching $1.36. The company had a trading volume of 1,055,764 shares, compared to its average volume of 1,002,462. The company has a market capitalization of $28.83, a price-to-earnings ratio of -1.43 and a beta of 1.93. Lipocine has a 1-year low of $1.30 and a 1-year high of $5.33.
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.